scholarly journals Mismatch between insulin-mediated glucose uptake and blood flow in the heart of patients with Type II diabetes

Diabetologia ◽  
2002 ◽  
Vol 45 (10) ◽  
pp. 1404-1409 ◽  
Author(s):  
Iozzo P. ◽  
Chareonthaitawee P. ◽  
Rimoldi O. ◽  
Betteridge D. ◽  
Camici P. ◽  
...  
Diabetologia ◽  
2001 ◽  
Vol 44 (6) ◽  
pp. 700-705 ◽  
Author(s):  
R. L. Perrott ◽  
R. V. North ◽  
N. Drasdo ◽  
K. A. Ahmed ◽  
D. R. Owens

2002 ◽  
Vol 102 (3) ◽  
pp. 307-314
Author(s):  
E.J. ABBINK ◽  
P. PICKKERS ◽  
A. Jansen VAN ROSENDAAL ◽  
J.A. LUTTERMAN ◽  
C.J. TACK ◽  
...  

Glibenclamide inhibits the opening of vascular ATP-sensitive potassium (KATP) channels, which represents a protective mechanism during ischaemia. This effect may imply harmful cardiovascular effects of glibenclamide when used under conditions of ischaemia in patients with Type II diabetes. Acarbose is not associated with effects on the cardiovascular system, because the drug is not absorbed from the bowel. Therefore we hypothesized that treatment of Type II diabetes patients with glibenclamide will impair the vasodilator function of KATP opening, unlike treatment with acarbose. A double-blind randomized cross-over study in 12 patients with Type II diabetes was performed to compare the effects of glibenclamide with those of acarbose on the vasodilator responses to KATP channel opening in the forearm vascular bed. The study consisted of two periods: 8 weeks of treatment with orally administered glibenclamide (10mgċday-1) followed by 8 weeks of treatment with acarbose (300mgċday-1), or vice versa. At the end of each treatment period, forearm blood flow (venous occlusion plethysmography) in response to intra-arterially administered diazoxide, acetylcholine and dipyridamole and to forearm ischaemia was measured. The diazoxide-mediated increase in the forearm blood flow ratio (infused/control arm) was significantly less pronounced after glibenclamide than after acarbose (290±58% and 561±101% respectively; P < 0.0005). Forearm blood flow responses to acetylcholine, dipyridamole and forearm ischaemia were similar during glibenclamide and acarbose treatment. Thus, in patients with Type II diabetes mellitus, treatment with glibenclamide is associated with an attenuated response to KATP opening as compared with treatment with acarbose. This implies that glibenclamide may affect defensive mechanisms under conditions of KATP channel activation.


2007 ◽  
Vol 39 (Supplement) ◽  
pp. S431
Author(s):  
Joohee Im ◽  
Sinclair Smith ◽  
Guoquiang Yu ◽  
Gwen Lech ◽  
Shoko Nioka ◽  
...  

2010 ◽  
Vol 109 (5) ◽  
pp. 1347-1353 ◽  
Author(s):  
Steven W. Copp ◽  
K. Sue Hageman ◽  
Brad J. Behnke ◽  
David C. Poole ◽  
Timothy I. Musch

The purpose of the present investigation was to examine the muscle hyperemic response to steady-state submaximal running exercise in the Goto-Kakizaki (GK) Type II diabetic rat. Specifically, the hypothesis was tested that Type II diabetes would redistribute exercising blood flow toward less oxidative muscles and muscle portions of the hindlimb. GK diabetic ( n = 10) and Wistar control ( n = 8, blood glucose concentration, 13.7 ± 1.6 and 5.7 ± 0.2 mM, respectively, P < 0.05) rats were run at 20 m/min on a 10% grade. Blood flows to 28 hindlimb muscles and muscle portions as well as the abdominal organs and kidneys were measured in the steady state of exercise using radiolabeled 15-μm microspheres. Blood flow to the total hindlimb musculature did not differ between GK diabetic and control rats (161 ± 16 and 129 ± 15 ml·min−1·100g−1, respectively, P = 0.18). Moreover, there was no difference in blood flow between GK diabetic and control rats in 20 of the individual muscles or muscle parts examined. However, in the other eight muscles examined that typically are comprised of a majority of fast-twitch glycolytic (IIb/IIdx) fibers, blood flow was significantly greater (i.e., ↑31–119%, P < 0.05) in the GK diabetic rats. Despite previously documented impairments of several vasodilatory pathways in Type II diabetes these data provide the first demonstration that a reduction of exercising muscle blood flow during submaximal exercise is not an obligatory consequence of this condition in the GK diabetic rat.


2002 ◽  
Vol 103 (4) ◽  
pp. 339-344 ◽  
Author(s):  
D. DARKO ◽  
A. DORNHORST ◽  
F.J. KELLY ◽  
J.M. RITTER ◽  
P.J. CHOWIENCZYK

Type II diabetes is characterized by increased oxidative stress, endothelial dysfunction and hypertension. We investigated whether short-term treatment with oral vitamin C reduces oxidative stress and improves endothelial function and blood pressure in subjects with Type II diabetes. Subjects (n = 35) received vitamin C (1.5g daily in three doses) or matching placebo for 3 weeks in a randomized, double-blind, parallel-group design. Plasma concentrations of 8-epi-prostaglandin F2α (8-epi-PGF2α), a non-enzymically derived oxidation product of arachidonic acid, were used as a marker of oxidative stress. Endothelial function was assessed by measuring forearm blood flow responses to brachial artery infusion of the endothelium-dependent vasodilator acetylcholine (with nitroprusside as an endothelium-independent control) and by the pulse wave responses to systemic albuterol (endothelium-dependent vasodilator) and glyceryl trinitrate (endothelium-independent vasodilator). Plasma concentrations of vitamin C increased from 58±6 to 122±10μmol/l after vitamin C, but 8-epi-PGF2α levels (baseline, 95±4pg/l; after treatment, 99±5pg/l), blood pressure (baseline, 141±5/80±2mmHg; after treatment, 141±5/81±3mmHg) and endothelial function, as assessed by the systemic vasodilator response to albuterol and by the forearm blood flow response to acetylcholine, were not significantly different from baseline or placebo. Thus treatment with vitamin C (1.5 g daily) for 3 weeks does not significantly improve oxidative stress, blood pressure or endothelial function in patients with Type II diabetes.


2018 ◽  
Vol 2018 ◽  
pp. 1-10 ◽  
Author(s):  
R. O. Malematja ◽  
V. P. Bagla ◽  
I. Njanje ◽  
V. Mbazima ◽  
K. W. Poopedi ◽  
...  

Background. Type II diabetes is on the rise while obesity is one of the strongest risk factors of type II diabetes. The search for a drug for type II that can equally mitigate obesity related complication is desired.Methods. The acetone leaf extract ofSenna italicawas evaluated for its cytotoxic, antiglycation, and lipolytic effect, glucose uptake, and GLUT4 translocation and expression using published methods, while that for adipogenesis and protein expression levels of obesity related adipokines was assessed using adipogenesis assay and mouse adipokine proteome profiler kit, respectively. The possible mechanism of glucose uptake was assessed through the inhibition of PI3K pathway.Results. The extract had no adverse effect on 3T3-L1 cell viability (CC50 > 1000 μg/ml). High antiglycation effect was attained at 10 mg/ml, while at 25–200 μg/ml it showed no significant increase in adipogenesis and lipolysis. The extract at 100 μg/ml was shown to decrease the expression levels of various adipokines and minimal glucose uptake at 50–100 μg/ml with a nonsignificant antagonistic effect when used in combination with insulin. GLUT4 translocation and expression were attained at 50–100 μg/ml with an increase in GLUT4 expression when in combination with insulin.Conclusion. The acetone leaf extract ofS. italicastimulates glucose uptake through the PI3K-dependent pathway and can serve as a source of therapeutic agent for the downregulation of obesity-associated adipokines in obesity and antiglycation agents.


2010 ◽  
Vol 42 ◽  
pp. 242
Author(s):  
Veronica Poitras ◽  
Michael Bravo ◽  
Melissa Pak ◽  
Michael E. Tschakovsky

2020 ◽  
Vol 281 ◽  
pp. 103518
Author(s):  
Alec L.E. Butenas ◽  
Joshua R. Smith ◽  
Steven W. Copp ◽  
K. Sue Hageman ◽  
David C. Poole ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document